72 results on '"Sandhu, Karamjeet"'
Search Results
2. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
3. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab
4. A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract
5. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy
6. Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL
7. Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide
8. Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens
9. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome‐positive acute lymphoblastic leukemia.
10. Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study.
11. Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome‐positive acute lymphoblastic leukemia.
12. Therapy‐related acute lymphoblastic leukaemia in women with antecedent breast cancer.
13. Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation
14. Health-Related Quality of Life in Double Umbilical Cord Blood versus Haploidentical Marrow Transplantation: A Quality of Life Analysis Report of BMT CTN 1101
15. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin
16. Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.
17. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia
18. Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
19. Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center
20. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
21. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents
22. Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis
23. Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations
24. AML-491 Real World Practice of FLAG-Idarubicin-Venetoclax in Relapsed Refractory AML: A Single Center Experience
25. Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
26. A review of low dose interleukin-2 therapy in management of chronic graft-versus-host-disease.
27. Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
28. Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia
29. WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens.
30. Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies
31. High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia‐like fusions.
32. Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience.
33. A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease.
34. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
35. Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
36. Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.
37. Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA‐Ven) or liposomal daunorubicin‐cytarabine (CPX‐351).
38. S262: SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE‐CEL), A FAST‐OFF RATE CD19 CAR IN RELAPSED/REFRACTORY ADULT B‐CELL ACUTE LYMPHOBLASTIC LEUKAEMIA:TOP LINE RESULTS OF THE PIVOTAL FELIX STUDY.
39. Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia.
40. Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia.
41. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
42. Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study.
43. Umbilical Cord Blood Transplantation Outcomes in Acute Myelogenous Leukemia/Myelodysplastic Syndrome Patients Aged ≥70 Years.
44. ALL-440: Promising Safety and Efficacy Results from an Ongoing Phase 1/2 Study of Pembrolizumab in Combination with Blinatumomab in Patients (pts) with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL).
45. Poster: ALL-440: Promising Safety and Efficacy Results from an Ongoing Phase 1/2 Study of Pembrolizumab in Combination with Blinatumomab in Patients (pts) with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL).
46. A Retrospective Study of Venetoclax-Based Salvage Regimen As a Bridge to Allogeneic Hematopoietic Cell Transplantation (HCT) in High-Risk Acute Myeloid Leukemia (AML) Patients.
47. Similar Invasive Fungal Infection Rates and Survival after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Bone Marrow or Peripheral Blood Graft Sources.
48. Concurrent versus sequential or no triazole anti-fungal therapy in patients undergoing 7 + 3 plus midostaurin induction for FLT-3 acute myelogenous leukemia.
49. Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
50. Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.